Skip to main content
SpringerLink
Log in

Estrogen Receptors in Prolactinomas: A Clinico-Pathological study

  • Published:
Pituitary Aims and scope Submit manuscript

Abstract

Background: Antiestrogens are effective in the treatment of estrogen receptor (ER) positive breast carcinoma. The use of antiestrogen therapy in pituitary adenomas, however, has not been explored. This study attempted to identify a population who may benefit from antiestrogen therapy.

Materials & Methods: Prolactinomas from 29 patients (10 men, 19 women) were analyzed for ER and Ki-67 labeling index using immunohistochemistry. Nine of the 19 women were either amenorrheic or had not received exogenous estrogen for at least one year. Ten women were menstruating either spontaneously or as a result of estrogen administration. Factors including age, serum prolactin level, tumor size, evidence of tumor invasiveness and recurrence of tumor were evaluated to determine if they were predictive of ER expression.

Results: Tumors from 6/10 (60%) men were positive for ER. Among women who were having menses, 9/10 (90%) tumors were positive, whereas 6/9 (67%) tumors from amenorrheic women were positive. Statistical analysis revealed that none of the variables: gender, age, menstrual status, Ki-67 proliferative rate, exposure to dopamine agonists, preoperative prolactin level, tumor size, or invasiveness was predictive for the presence of the receptor. The incidence of ER, however, was significantly reduced in recurrent tumors (p=0.03).

Conclusions: ER expression is less likely in recurrent tumors. The efficacy of ER antagonists cannot be inferred by gender or estrogen exposure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Thomson JA, Davies DL, McLaren EH, Teasdale GM. Ten year follow-up of microprolactinoma treated by transsphenoidal surgery. BMJ 1994;309:1409-1410.

    Google Scholar 

  2. Thomson JA, Teasdale GM, Gordon D, McCruden DC, Davies DL. Treatment of presumed prolactinoma by transsphenoidal operation: early and late results. BMJ 1985;291:1550-1553.

    Google Scholar 

  3. Randall RV, Laws ER, Abboud CF, Ebersold MJ, Kao PC, Scheithauer BW. Transsphenoidal microsurgical treatement of prolactin-producing pituitary adenomas. Results in 100 patients. Mayo Clin Proc 1983;58:108-121.

    Google Scholar 

  4. Gooren LJG, Assies J, Asscheman H, de Slegte R, van Kessel H. Estrogen induced prolactinoma in a man. J Clin Endocrinol Metab 1988;66:444-446.

    Google Scholar 

  5. Gooren LJG, Harmsen-Louman W, van Kessel H. Follow-up of prolactin levels in long-term oestrogen-treated male-to-female transsexuals with regard to prolactinoma induction. Clin Endocrinol 1985;22:201-207.

    Google Scholar 

  6. Fujimoto M, Yoshino E, Mizukawa N, Hirakawa K. Spontaneous reduction in size of prolactin-producing adenoma after delivery. J Neurosurg 1985;63:973-974.

    Google Scholar 

  7. Holmgren U, Bergstrand G, Hagenfeldt K, Werner S. Women with prolactinoma-effect of pregnancy and lactation on serum prolactin and on tumour growth. Acta Endocrinol 1986;111:452-459.

    Google Scholar 

  8. Kovacs K, Stefaneanu L, Ezzat S, Smyth HS. Prolactin-producing pituitary adenoma in a male-to-female transsexual patient with protracted estrogen administration. A morphologic study. Arch Pathol Lab Med 1994;118:562-565.

    Google Scholar 

  9. Panteon E, Loumaye E, Maes M, Malvaux P. Occurence of prolactinoma after estrogen treatment in a girl with constitutional tall stature. J Pediatric 1988;113:337-339.

    Google Scholar 

  10. Maurer RA, Notides AC. Identification of an estrogen-responsive element from the 5'-flanking region of the rat prolactin gene. Molec Cell Biol 1987;7:4247-4254.

    Google Scholar 

  11. Rose C, Andersen KW, Mouridsen HT, Thorpe SM, Pedersen BV, Blichert-Toft M, Rasmussen BB. Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values. Lancet 1985;1:16-19.

    Google Scholar 

  12. Carroll RS, Zhang J, Dashner K, Sar M, McL Black P. Steroid hormone receptors in astrocytic neoplasms. Neurosurg 1995;37:496-504.

    Google Scholar 

  13. Fujimoto M, Yoshino E, Hirakawa K, Fujimoto J, Tamaya T. Estrogen receptors in brain tumors. Clin Neuropharmacol 1984;7:357-362.

    Google Scholar 

  14. Stojkovic RR, Jovancevic M, Santel DJ, Grcevic N, Gamulin S. Sex steroid receptors in intracranial tumors. Cancer 1990;65:1968-1970.

    Google Scholar 

  15. Friend KE, Chiou YK, Lopes MBS, Laws ER, Hughes KM, Shupnik MA. Estrogen receptor expression in human pituitary: correlation with immunohistochemistry in normal tissue, and immunohistochemistry and morphology in macroadenomas. J Clin Endocrinol Metab 1994;78: 1497-1504.

    Google Scholar 

  16. Pichon MF, Bression D, Peillon F, Milgrom E. Estrogen receptors in human pituitary adenomas. J Clin Endocrinol Metabol 1980;51:897-902.

    Google Scholar 

  17. Nakao J, Koga M, Arao M, et al. Enzyme-immunoassay for estrogen receptors in human pituitary adenomas. Acta Endocrinol (Copenh) 1989;120:233-238.

    Google Scholar 

  18. Stefaneanu L, Kovacs K. Immunocytochemical approach to demonstrate the estrogen receptor in human adenohypophyses and pituitary adenomas with monoclonal antibody. Med Sci Res 1988;16:449-450.

    Google Scholar 

  19. Barrow DL, Mizuno J, Tindall GT. Management of prolactinomas associated with very high serum prolactin levels. J Neurosug 1988;68:554-558.

    Google Scholar 

  20. Bevan JS, Adams CBT, Burke CW, Morton KE, Molyneux AJ, Moore RA, Esiri MM. Factors in the outcome of transsphenoidal surgery for prolactinoma and non-functioning pituitary tumor, including pre-operative bromocriptine therapy. Clin Endocrinol 1987;26:541-556.

    Google Scholar 

  21. Faria MA, Tindall GT. Transsphenoidal microsurgery for prolactin-secreting pituitary adenomas. Results in 100 women with the amenorrhea-galactorrhea syndrome. J Neurosurg 1982;56:33-43.

    Google Scholar 

  22. Laws ER, Ebersold MJ, Piepgras DG, Abboud CF, Randall RV, Scheithauer BW. The role of surgery in the management of prolactinoma. In: MacLeod RM, Thorner MO, Scapagnini U eds. Prolactin basic and clinical correlates. Padova: Livinia Press, 1985:849-853.

    Google Scholar 

  23. Nelson PB, Goodman M, Maroon JC, Martinez J, Moossy J, Robinson AG. Factors in predicting outcome from operation in patients with prolactin-secreting pituitary adenomas. Neurosurg 1983;13:634-641.

    Google Scholar 

  24. Randall RV, Scheithauer BW, Laws ER, Abboud CF, Ebersold MJ, Kao PC. Pituitary adenomas associated with hyperprolactinemia: a clinical and immunohistochemical study of 97 patients operated on transsphenoidally. Mayo Clin Proc 1985;60:753-762.

    Google Scholar 

  25. Selman WR, Laws ER, Scheithauer BW, Carpenter SM. The occurrence of dural invasion in pituitary adenomas. J Neurosurg 1986;64:402-407.

    Google Scholar 

  26. Thapar K, Kovacs K, Scheithauer BW et al. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using MIB-1 antibody. Neurosurg 1996;38:99-107.

    Google Scholar 

  27. Wilson CB. A decade of pituitary microsurgery. The Herbert Olivecrona Lecture. J Neurosurg 1984;61:814-833.

    Google Scholar 

  28. Hsu S, Raine L, Fanger H. The use of antiavidin antibody and avidin-biotin-peroxidase complex in immunoperoxidase technics. Am Soc Clin Pathol 1981;75:816-821.

    Google Scholar 

  29. Shi S, Key ME, Kalra KL. Antigen retrieval in formalin-fixed, paraffin embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 1991; 39:741-748.

    Google Scholar 

  30. Nichols GE, Frierson HF, Boyd JC, Hanigan MH. Automated immunohistochemical analysis for estrogen receptor status in breast cancer using monoclonal antibody CC4-5 on Ventana ES. Am J Clin Pathol 1996;106:332-338.

    Google Scholar 

  31. Harris JR, Morrow M, Bonadonna G. Cancer of the breast. In: Devita VT, Hellman S, Rosenberg SA eds. Cancer: principles and practice of oncology, 4 th ed. Philadelphia: J. B. Lippincott, 1994:1264-1330.

    Google Scholar 

  32. de Quijada M, Timmermans HAT, Lamberts SWJ. Tamoxifen suppresses both the growth of prolactin-secreting pituitary tumors and normal prolactin synthesis in the rat. J Endocrinol 1980;86:109-116.

    Google Scholar 

  33. de Quijada M, Timmermans HAT, Lamberts SWJ, MacLeod RM. Tamoxifen enhances the sensitivity of dispersed prolactin-secreting pituitary tumor cells to dopamine and bromocriptine. Endocrinol 1980;106:702-706.

    Google Scholar 

  34. Lamberts SWJ, Verleun T, Oosterom R. Effect of tamoxifen administration on prolactin release by invasive prolactin-secreting pituitary adenomas. Neuroendocrinol 1982;34: 339-342.

    Google Scholar 

  35. Volker W, Gehring WG, Berning R, Schmidt RC, Scheider J, von zur Muhlen A. Impaired pituitary response to bromocriptine suppresion: reversal after bromocriptine plus tamoxifen. Acta Endocrinol 1982;101:491-500.

    Google Scholar 

  36. Breast Cancer Trials Committee. Lancet 1987;2:171-175.

    Google Scholar 

  37. Lloyd RV: Estrogen-induced hyperplasia and neoplasia in the rat anterior pituitary gland. An immunohistochemical study. Am J Pathol 1983;113:198-206.

    Google Scholar 

  38. Buckman MT, Peake GT, Srivastava LS. Periovulatory enhancement of spontaneous prolacin secretion in normal women. Metabolism 1980;29:753-757.

    Google Scholar 

  39. Franks S. Regulation of prolactin secretion by oestrogens: physiological and pathological significance. Clin Sci 1983;65:457-462.

    Google Scholar 

  40. Hulting AL, Werner S, Hagenfeldt K. Oral contraceptive steroids do not promote the development or growth of prolactinomas. Contracep 1983;27:69-73.

    Google Scholar 

  41. Hsu DW, Efird JT, Hedley-Whyte ET. Progesterone and estrogen receptors in meningiomas: prognostic considerations. J Neurosurg 1997;86:113-120.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, University of Virginia Health Sciences Center, Charlottesville, VA

    G.J. Kaptain, N.E. Simmons, T.D. Alden, M.B. Lopes & E.R. Laws

  2. Department of Medicine, Division of Endocrinology, University of Virginia Health Sciences Center, Charlottesville, VA

    M.L. Vance

Authors
  1. G.J. Kaptain
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N.E. Simmons
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T.D. Alden
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M.B. Lopes
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M.L. Vance
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E.R. Laws
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kaptain, G., Simmons, N., Alden, T. et al. Estrogen Receptors in Prolactinomas: A Clinico-Pathological study. Pituitary 1, 91–98 (1999). https://doi.org/10.1023/A:1009903603495

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1009903603495

Search

Navigation